Over a month ago |
Earnings
|
Sees FY23 adjusted EBITDA… Sees FY23 adjusted EBITDA $149M-$153M. ShowHide Related Items >><< - 02/08/23
- Perion Network announces six-month CEO transition period
- 01/30/23 Needham
- Perion Network price target raised to $37 from $32 at Needham
- 01/20/23 Lake Street
- Lake Street 'comfortable' with revenue growth forecast for Perion Network
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 02/08/23
- Perion Network reports Q4 adjusted EPS 90c, consensus 59c
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Fly Intel: Pre-market Movers
- 10/06/22
- What You Missed On Wall Street On Thursday
- 12/09/22
- Largest borrow rate increases among liquid names
- 12/06/22
- Largest borrow rate increases among liquid names
- 11/25/22
- Largest borrow rate increases among liquid names
|
Earnings
|
Reports Q4 revenue… Reports Q4 revenue $209.7M, consensus $205M. ShowHide Related Items >><< - 02/08/23
- Perion Network announces six-month CEO transition period
- 01/30/23 Needham
- Perion Network price target raised to $37 from $32 at Needham
- 01/20/23 Lake Street
- Lake Street 'comfortable' with revenue growth forecast for Perion Network
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Fly Intel: Pre-market Movers
- 10/06/22
- What You Missed On Wall Street On Thursday
- 12/09/22
- Largest borrow rate increases among liquid names
- 12/06/22
- Largest borrow rate increases among liquid names
- 11/25/22
- Largest borrow rate increases among liquid names
|
Hot Stocks
|
Perion Network announced… Perion Network announced that it is entering a six-month CEO transition period. Tal Jacobson, currently General Manager of CodeFuel, Perion's search advertising business, will be promoted to CEO of Perion on August 1. Following Jacobson's promotion, Gerstel will step down from the executive team and remain on the Board of Directors to ensure business continuity and a smooth transition. "Perion is well-positioned for sustained, profitable growth, and the time is right for me to turn the company over to the next generation of leadership" commented Gerstel. "Having been CEO of five different companies since 1999, I feel the need to take some time off to re-energize. I asked Tal to join Perion more than four years ago and have no doubt that he is the ideal person to lead Perion forward. Tal has done remarkable work at CodeFuel." Tal Jacobson has been an ad-tech executive and leader for more than two decades. Tal joined Perion in 2018 as the General Manager of CodeFuel, transforming Perion's search advertising, from a fledgling business unit in decline, into a significant driver of Perion's soaring market share and valuation, cementing the strategic relationship with Microsoft and winning Microsoft Advertising Global supply partner of the year award. ShowHide Related Items >><< - 01/30/23 Needham
- Perion Network price target raised to $37 from $32 at Needham
- 01/20/23 Lake Street
- Lake Street 'comfortable' with revenue growth forecast for Perion Network
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Fly Intel: Pre-market Movers
- 10/06/22
- What You Missed On Wall Street On Thursday
- 12/09/22
- Largest borrow rate increases among liquid names
- 12/06/22
- Largest borrow rate increases among liquid names
- 11/25/22
- Largest borrow rate increases among liquid names
|
Recommendations
|
Needham analyst Laura… Needham analyst Laura Martin raised the firm's price target on Perion Network (PERI) to $37 from $32 and keeps a Buy rating on the shares. The company should be a a key beneficiary of the DOJs anti-trust lawsuit against Alphabet (GOOGL) because over 40% of its revenue is attributable to Bing, the #2 search engine, the analyst tells investors in a research note. Any remedies that weaken Google Search help Bing, and Perion Network is one of the largest Bing affiliates, the firm adds. ShowHide Related Items >><< - 01/27/23
- Google to comply with EU rules around providing clearer info to consumers
- 01/24/23
- Google's Dan Taylor says DOJ lawsuit 'tries to rewrite history'
- 01/24/23
- States, Department of Justice sue Google alleging advertising 'monopoly'
- 01/24/23
- Justice Department, eight states file antitrust suit against Google
- 01/20/23 Lake Street
- Lake Street 'comfortable' with revenue growth forecast for Perion Network
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/31/22 Stifel
- Perion Network resumed with a Buy at Stifel
- 01/26/23 Jefferies
- Jefferies sees attractive risk/reward with Alphabet multiple near 15-year trough
- 01/26/23 Oppenheimer
- Alphabet price target lowered to $130 from $135 at Oppenheimer
- 01/25/23 MKM Partners
- Alphabet price target lowered to $120 from $130 at MKM Partners
- 01/25/23 Credit Suisse
- Alphabet price target raised to $145 from $128 at Credit Suisse
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 10/25/22
- Alphabet reports Q3 EPS $1.06, consensus $1.25
- 10/25/22
- Notable companies reporting after market close
- 01/26/23
- Confluent Chief Revenue Officer departs, The Information reports
- 01/25/23
- Institutional hedge fund manager want more Google job cuts, The Register says
- 01/25/23
- Hawley to introduce bill to implement nationwide ban on TikTok, Fox reports
- 01/25/23
- Alphabet's Waymo quietly lays off staff, The Information reports
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Fly Intel: Pre-market Movers
- 10/06/22
- What You Missed On Wall Street On Thursday
- 01/25/23
- #SocialStocks: Musk refutes veracity of WSJ story that he seeks $3B in funding
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/24/23
- What Wall Street is saying about Microsoft ahead of earnings
- 01/24/23
- What You Missed On Wall Street This Morning
- 12/09/22
- Largest borrow rate increases among liquid names
- 12/06/22
- Largest borrow rate increases among liquid names
- 11/25/22
- Largest borrow rate increases among liquid names
- 01/20/23
- Early notable gainers among liquid option names on January 20th
- 01/20/23
- Unusually active option classes on open January 20th
- 12/05/22
- Alphabet Class A call volume above normal and directionally bullish
- 11/04/22
- Notable open interest changes for November 4th
|
Recommendations
|
Lake Street analyst Eric… Lake Street analyst Eric Martinuzzi tells investors in a research note that while layoffs at Alphabet (GOOGL) continue to weigh on ad tech sector sentiment, the analyst is comfortable with his 14% revenue growth forecast for Perion Network (PERI) in 2023. Perion's positive preliminary Q4 results were in part driven by a 25% increase in publishing partners, Martinuzzi says, and made no change to the firm's Buy rating or $36 price target. ShowHide Related Items >><< - 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/31/22 Stifel
- Perion Network resumed with a Buy at Stifel
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Fly Intel: Pre-market Movers
- 10/06/22
- What You Missed On Wall Street On Thursday
- 12/09/22
- Largest borrow rate increases among liquid names
- 12/06/22
- Largest borrow rate increases among liquid names
- 11/25/22
- Largest borrow rate increases among liquid names
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 11/16/22
- ZoomInfo sees 4% sequential growth in Q4, possible 4%-5% per quarter in 2023
- 11/16/22
- ZoomInfo Technologies trading resumes
- 11/16/22
- ZoomInfo Technologies trading halted, volatility trading pause
- 11/16/22
- ZoomInfo down 15% following conference presentation
- 01/03/23
- Vera Therapeutics shares fall 67% despite ORIGIN trial meeting primary endpoint
- 01/03/23
- Vera Therapeutics announces ORIGIN clinical trial met primary endpoint
- 11/17/22
- Vera Therapeutics to host KOL webinar on targeting the source of IgAN
- 11/09/22
- Vera Therapeutics expects cash to fund oeprations into 2Q24
- 12/08/22
- Veeva director sells $1.64M in common stock
- 12/02/22
- Veeva falls -7.3%
- 11/01/22
- Veeva, Merck establish ten-year strategic partnership agreement
- 10/04/22
- Veeva announces over 350 companies using Veeva Vault RIM Suite applications
- $198.85 /
+9.375 (+4.95%) - 10/25/22
- UniFirst increases quarterly common stock dividend to 31c per share
- 12/11/22
- Fly Intel: Top five weekend stock stories
- 11/28/22
- Texas Instruments announces expansion of its portfolio
- 10/25/22
- Texas Instruments falls 5% to $154.39 after Q4 guidance misses estimates
- 10/25/22
- Texas Instruments: Experienced expected weakness in personal electronics in Q3
- 12/06/22
- TSMC to triple U.S. chip investment to $40B
- 11/14/22
- TSMC jumps 7% to $77.91 after Berkshire Hathaway disclosed added stake
- 10/26/22
- Synopsys, TSMC partner over multi-die design solutions
- 01/04/23
- Toyota Motor North America reports year-end 2022 U.S. sales 2,108,458 vehicles
- 12/27/22
- Toyota reports November worldwide sales rose 2.9% to 796,484 units
- 12/15/22
- Toyota, Oncor partner on EV charging ecosystem
- 01/04/23
- Theratechnologies focused on achieving positive EBITDA in the near-term
- 01/04/23
- Theratechnologies forms committee for Protocol Amendment for TH1902 trial
- 01/04/23
- Theratechnologies CEO says positioned 'product portfolio for commercial success'
- 12/01/22
- Theratechnologies trading resumes
- 12/22/22
- Target recalls roughly 204,000 children's weighted blankets after two deaths
- 11/25/22
- Target announces Cyber Monday sales event from Nov. 27-28
- 11/17/22
- Target announces largest Black Friday week sale ever from Nov. 20-26
- 11/16/22
- Target falls -15.8%
- 01/03/23
- SGH spikes almost 9% after reporting Q1 results that beat expectations
- 11/16/22
- SGH's Penguing Computing to acquire software assets from Colorado Code Craft
- 09/14/22
- Cree LED, Tomar Electronics enter settlement, limited license agreement
- 07/28/22
- SGH CEO buys $181K in common stock stock
- 12/12/22
- Boston Beer's TeaPot launches merchandise collaboration with Peace Collective
- 07/21/22
- Boston Beer drops 10% to $303.40 after lowering FY22 EPS guidance
- 01/04/23
- Visteon, Qualcomm collaborate on development of digital cockpit
- 11/02/22
- Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates
- 11/02/22
- Qualcomm sees low-double digits handset volume declines for 2022
- 10/25/22
- Cognizant expands collaboration with Qualcomm
- 12/29/22
- Pfizer discloses 5.38M share stake in Oric Pharmaceuticals
- 12/29/22
- Pfizer announces topline results from Phase 3 study of fidanacogene elaparvovec
- 12/28/22
- Pfizer announces FDA acceptance of BLA for MenABCWY in adolescents
- 12/26/22
- Fly Intel: Top five weekend stock stories
- 11/01/22
- Fox Corp.: Special Committee has not made any determination on News Corp.
- 10/14/22
- Fox Corp. forms committee to begin exploring potential News Corp. combination
- 12/12/22
- News Corp. appoints Emma Tucker as Editor-in-Chief of The Wall Street Journal
- 12/06/22
- Fox Corp. provides update on potential News Corp. transaction
- 12/05/22
- News Corp. special committee to explore combination with Fox Corp.
- 11/08/22
- News Corp. says Special Committee has not decided on pursuit of Fox deal
- 01/03/23
- Foxconn, Nvidia partner to build automated electric vehicles
- 12/14/22
- IonQ hires Rima Alameddine as Chief Revenue Officer
- 12/07/22
- KULR Technology expands KULR VIBE offering with AI server platform
- 01/02/23
- Fly Intel: Top five weekend stock stories
- 12/30/22
- Micron slides 2% to $49.60 in pre-market after Argus downgrade to Hold
- 12/21/22
- Micron suspends share buybacks
- 12/21/22
- Micron slips about 1% to $50.70 after Q1 earnings miss and guidance
- $229.06 /
-10.67 (-4.45%) - 12/28/22
- Third Activision Blizzard video game unit seeks union
- 12/18/22
- Fly Intel: Top five weekend stock stories
- 12/16/22
- ReNew Energy Global signs 150 MW agreement with Microsoft
- 12/15/22
- Microsoft names Melanie Nakagawa as new Chief Sustainability Officer
- 12/01/22
- Marvell falls 7% to $42.29 after Q3 results, Q4 guidance miss estimates
- 12/01/22
- Marvell reports Q3 adjusted gross margin 64%
- 11/30/22
- Marvell extends collaboration with Nokia
- 10/03/22
- Marvell CEO Carl Hull to switch roles, William Martin to succeed
- $125.17 /
+2.675 (+2.18%) - 12/20/22
- 3M to exit PMAS manufacturing by 2025
- 11/21/22
- 3M announces reseller agreement with Rad AI
- 11/10/22
- California AG sues DuPont, 3M over 'toxic forever chemicals'
- 10/13/22
- 3M V.A.C. Therapy NPWT achieves medical evidence milestone
- 01/04/23
- Irish Data Protection Commission reports conclusion of inquiries into Meta
- 01/04/23
- Meta to appeal both 'substance' of Irish DPC rulings and fines
- 12/23/22
- Meta to settle Cambridge Analytica scandal case for $725M
- 12/19/22
- EU sends Statement of Objections to Meta over 'abusive practices' in Marketplace
- 11/10/22
- Microchip announces LAN8840, LAN8841 Gigabit Ethernet transceiver devices
- 10/26/22
- Microchip announces PIC32CXMT family of 32-bit microprocessors
- 10/19/22
- Microchip intoduces Arm Cortex - M4F-based PIC MCU family
- 09/19/22
- Microchip announces META-DX2 Ethernet PHY portfolio
- 01/04/23
- Mobileye in pact with Wistron NeWeb for software-defined imaging radars
- 10/31/22
- Mobileye CEO buys $10M in common stock
- 10/27/22
- Intel reports Q3 Mobileye revenue $450M
JEF Jefferies Financial Group - $38.70 /
+4.485 (+13.11%) - 12/02/22
- Ebix engages Jefferies as exclusive investment bank
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 11/01/22
- Jefferies Financial Group completes merger with Jefferies Group LLC
- 09/28/22
- Jefferies Financial Group 'increases buyback authorization back to $250M'
- 01/03/23
- Intel announces 13th Gen Core mobile processors plus N-series at CES
- 12/29/22
- Check Point expands collaboration with Intel for anti-ransomware capabilities
- 11/29/22
- Synopsys appoints Shelagh Glaser as CFO
- 12/14/22
- Robinhood raising interest rates for Gold members to 4%
- 12/07/22
- Robinhood reports November MAUs 12.5M
- 12/06/22
- Robinhood CEO says regulators should scrutinize offshore crypto companies
- 12/06/22
- Robinhood opens waitlist for 'Robinhood Retirement' product
- $11.08 /
+1.135 (+11.41%) - 01/04/23
- Hayward rises 9.6%
- 11/01/22
- Hayward rises 13.2%
- 01/04/23
- General Motors reports Q4 U.S. sales up 41% to 623,261 units
- 12/20/22
- Cruise's driverless robotaxis are taking passengers in Phoenix and Austin
- 12/16/22
- NHTSA opens probe into GM's Cruise autonomous driving system
- 12/15/22
- EU passenger car registrations up 16.3% in November
- 01/04/23
- Geron up 48% in pre-market at $3.54 after Phase 3 trial data for imetelstat
- 01/04/23
- Geron reports 'positive' results from IMerge Phase 3 trial of imetelstat
- 08/22/22
- Geron doses first patient in IMproveMF phase 1 study
- 01/04/23
- GE HealthCare completes spin-off from GE, starts trading on Nasdaq
- 12/28/22
- GE HealthCare to replace Vornado Realty Trust in the S&P500 at open on January 4
- 11/30/22
- General Electric board approves separation of GE HealthCare
- $70.18 /
-14.845 (-17.46%) - 01/04/23
- General Electric falls -19.3%
- 01/04/23
- General Electric falls -21.0%
- 01/04/23
- General Electric falls -20.0%
- 11/04/22
- Fox Corp. 'pleased' with 'fair and favorable outcome' of Flutter arbitration
- 11/03/22
- Fox Corp. partners with FreeWheel for OneFOX inventory
- 01/03/23
- Deciphera announces results from ctDNA analysis from Intrigue Phase 3 trial
- 09/11/22
- Deciphera presents updated Phase 1/2 Data for vimseltinib in TGCT
- 09/10/22
- Deciphera presnts initial Phase 1 single agent dose escalation data for DCC-3116
- 08/10/22
- Deciphera announces publication of INTRIGUE study results in journal
- 01/04/23
- Salesforce up 4% to $139.85 after announcing restructuring
- 01/04/23
- Salesforce announces restructuring, 10% workforce reduction
- 12/08/22
- Salesforce CEO: Planning for CRM to be second largest software company
- 12/06/22
- Sprout, Salesforce deepen partnership with addition of Tableau
- $103.98 /
+12.025 (+13.08%) - 12/29/22
- Alibaba names new CTO as CEO steps in interim cloud head
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 12/23/22
- PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline
- 11/17/22
- Tims China announces partnership with Alibaba's Freshippo
- 12/20/22
- EU opens antitrust probe into Broadcom's proposed $61B VMware bid
- 12/01/22
- AMD, Viettel collaborate on 5G mobile network expansion
- 11/23/22
- Third quarter CPU shipments down 18.6% compared to Q321, JPR says
- 11/17/22
- AMD, Analog Devices resolve all ongoing patent litigations
- $26.15 /
+3.125 (+13.57%) - 11/23/22
- RocketFuel Blockchain announces launch of loyalty token $Rpay
- 11/21/22
- ACI Worldwide, NTT Data to partner to advance Europe and Latin America market
- 11/14/22
- Starboard takes stake in Wix.com, exits Elanco Animal Health
- 11/08/22
- ACI Worldwide names Thomas Warsop interim CEO
- 07/10/22 Goldman Sachs
- News Corp. downgraded to Buy from Conviction Buy at Goldman Sachs
- 10/17/22 Morgan Stanley
- Morgan Stanley says Fox-News combo would balance more scale with more complexity
- 10/17/22 Loop Capital
- News Corp. downgraded to Hold from Buy at Loop Capital
- 10/17/22 Credit Suisse
- Fox Corp. downgraded to Neutral from Outperform at Credit Suisse
- 07/28/22 Macquarie
- News Corp. downgraded to Neutral at Macquarie ahead of expected 'soft' report
- $125.17 /
+2.675 (+2.18%) - 12/09/22 Citi
- 3M price target raised to $126 from $117 at Citi
- 11/16/22
- 3M followers suggest 'company might be ripe for activist,' says Gordon Haskett
- 10/26/22 Deutsche Bank
- 3M price target raised to $127 from $126 at Deutsche Bank
- 10/26/22 Mizuho
- 3M price target lowered to $130 from $140 at Mizuho
- 11/01/22 Nomura
- Sumitomo Mitsui resumed with a Buy at Nomura
- 06/23/22 BofA
- Sumitomo Mitsui upgraded to Buy from Neutral at BofA
- 04/27/22 Goldman Sachs
- Sumitomo Mitsui initiated with a Buy at Goldman Sachs
- 04/11/22 BofA
- Sumitomo Mitsui downgraded to Neutral from Buy at BofA
JEF Jefferies Financial Group - $38.70 /
+4.485 (+13.11%) - 12/21/22 Keefe Bruyette
- Jefferies downgraded to Market Perform from Outperform at Keefe Bruyette
- 12/21/22 Keefe Bruyette
- Jefferies Financial Group downgraded to Market Perform from Outperform at Keefe Bruyette
- 09/05/22 Keefe Bruyette
- Jefferies upgraded to Outperform from Market Perform at Keefe Bruyette
- 07/18/22 Morgan Stanley
- Jefferies Financial Group price target lowered to $28 from $32 at Morgan Stanley
- 06/02/22 Wolfe Research
- Fox Corp. assumed at Peer Perform from Outperform at Wolfe Research
- 04/19/22 Rosenblatt
- Fox Corp. initiated with a Neutral at Rosenblatt
- 01/04/23 Macquarie
- Fox Corp. price target lowered to $30 from $32 at Macquarie
- 01/03/23 Wolfe Research
- Fox Corp. downgraded to Underperform from Peer Perform at Wolfe Research
- 01/03/23 Wolfe Research
- Fox Corp. downgraded to Underperform from Peer Perform at Wolfe Research
- 11/02/22 RBC Capital
- Fox Corp. price target lowered to $38 from $46 at RBC Capital
- 12/19/22 Barclays
- Robinhood price target lowered to $9 from $10 at Barclays
- 12/12/22 Citi
- Robinhood downgraded to Neutral from Buy at Citi
- 12/12/22 Mizuho
- Fiserv price target lowered to $135 from $145 at Mizuho
- 12/02/22 Piper Sandler
- Piper calls for 'more aggressive headcount reduction' at Coinbase
- $26.15 /
+3.125 (+13.57%) - 11/03/22 Craig-Hallum
- ACI Worldwide price target lowered to $30 from $38 at Craig-Hallum
- 11/02/22 Needham
- ACI Worldwide downgraded to Hold at Needham with headwinds seen persisting
- 11/02/22 Needham
- ACI Worldwide downgraded to Hold from Buy at Needham
- 11/02/22 BTIG
- ACI Worldwide price target lowered to $31 from $46 at BTIG
- 01/05/23 TD Cowen
- Salesforce price target lowered to $175 from $195 at Cowen
- 01/04/23 Jefferies
- Salesforce restructuring plan 'a step in the right direction,' says Jefferies
- 12/08/22 Baird
- Baird downgrades Salesforce on macro, executive turnover concerns
- 12/08/22 Baird
- Salesforce downgraded to Neutral from Outperform at Baird
- 01/04/23 Edward Jones
- GE HealthCare initiated with a Hold at Edward Jones
- 12/06/22 Oppenheimer
- General Electric upgraded to Outperform from Perform at Oppenheimer
- $70.18 /
-14.845 (-17.46%) - 12/16/22 Barclays
- General Electric price target raised to $96 from $92 at Barclays
- 12/09/22 RBC Capital
- General Electric price target raised to $98 from $93 at RBC Capital
- 12/09/22 Citi
- General Electric price target raised to $100 from $87 at Citi
- 12/08/22 Oppenheimer
- Oppenheimer backs Outperform on GE amid weakness
- 01/05/23 Mizuho
- Meta Platforms price target raised to $170 from $160 at Mizuho
- 01/04/23 New Street
- New Street starts Meta Platforms with a Buy, thinks ad revenue can outperform
- 01/03/23 New Street
- Meta Platforms initiated with a Buy at New Street
- 12/16/22 JPMorgan
- Meta Platforms upgraded to Overweight from Neutral at JPMorgan
- 11/18/22 Wedbush
- GM's Investor Day event 'impressive,' says Wedbush
- 11/10/22 Wolfe Research
- General Motors downgraded to Peer Perform from Outperform at Wolfe Research
- 10/26/22 Deutsche Bank
- General Motors price target lowered to $35 from $36 at Deutsche Bank
- 10/26/22 JPMorgan
- General Motors price target raised to $59 from $58 at JPMorgan
- 10/13/22 Citi
- Toyota downgraded to Neutral at Citi on lower earnings outlook
- 10/13/22 Citi
- Toyota downgraded to Neutral from Buy at Citi
- 10/06/22 UBS
- Toyota downgraded to Neutral at UBS on lower profit forecasts
- 10/06/22 UBS
- Toyota downgraded to Neutral from Buy at UBS
- 01/02/23 Rosenblatt
- Rosenblatt reveals 15 best stock ideas for 2023
- 12/30/22 Argus
- Argus cuts Micron to Hold, sees potential operating losses over coming quarters
- 12/30/22 Oppenheimer
- Oppenheimer remain buyers of Enovix after CEO announcement
- 12/30/22 Argus
- Micron downgraded to Hold from Buy at Argus
- $103.98 /
+12.025 (+13.08%) - 11/18/22 Benchmark
- Alibaba price target lowered to $180 from $206 at Benchmark
- 11/18/22 UBS
- Alibaba price target lowered to $135 from $140 at UBS
- 11/18/22 Truist
- Alibaba price target lowered to $120 from $125 at Truist
- 11/18/22 Baird
- Alibaba price target lowered to $120 from $140 at Baird
- 12/15/22 Morgan Stanley
- AMD named 'Top Pick' in Semiconductors at Morgan Stanley
- 11/15/22 Credit Suisse
- Intel assumed with a Neutral at Credit Suisse
- 11/15/22 Credit Suisse
- AMD assumed with an Outperform at Credit Suisse
- 12/13/22 Northland
- Northland starts FormFactor at Outperform with $33 price target
- 12/01/22 New Street
- Mobileye initiated with a Buy at New Street
- 11/22/22 Mizuho
- Intel resumed with a Neutral at Mizuho
- 11/21/22 Morgan Stanley
- Mobileye initiated with an Equal Weight at Morgan Stanley
- 12/02/22 Craig-Hallum
- Marvell price target lowered to $63 from $90 at Craig-Hallum
- 12/02/22 BMO Capital
- Marvell price target lowered to $65 from $75 at BMO Capital
- 12/02/22 Jefferies
- Jefferies would 'buy the confession' after Marvell guidance miss
- 11/29/22 Stifel
- Microchip price target raised to $80 from $77 at Stifel
- 11/15/22 Credit Suisse
- Microchip initiated with a Neutral at Credit Suisse
- 11/04/22 UBS
- Microchip price target lowered to $90 from $100 at UBS
- 11/03/22 Piper Sandler
- Microchip price target lowered to $80 from $100 at Piper Sandler
- 12/19/22 Needham
- Nvidia price target raised to $230 from $200 at Needham
- 12/15/22 HSBC
- Nvidia initiated with a Reduce at HSBC
- 12/14/22 Deutsche Bank
- Nvidia price target raised to $170 from $150 at Deutsche Bank
- 12/20/22 JPMorgan
- Qualcomm price target lowered to $160 from $185 at JPMorgan
- 12/12/22 Wells Fargo
- Wells Fargo downgrades Qualcomm to Underweight with $105 price target
- 12/12/22 Wells Fargo
- Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo
- 11/15/22 Credit Suisse
- Qualcomm initiated with an Outperform at Credit Suisse
- 12/14/22 Deutsche Bank
- Texas Instruments price target raised to $158 from $155 at Deutsche Bank
- 11/15/22 Credit Suisse
- Texas Instruments assumed with Neutral from Outperform at Credit Suisse
- 11/01/22 Craig-Hallum
- Lattice Semiconductor price target lowered to $50 from $58 at Craig-Hallum
- 10/26/22 Susquehanna
- Texas Instruments price target lowered to $195 from $215 at Susquehanna
- 11/18/22 Erste Group
- TSMC upgraded to Buy from Hold at Erste Group
- 10/17/22 Northland
- Teradyne price target lowered to $74 from $85 at Northland
- 10/13/22 Goldman Sachs
- TSMC downgraded to Buy from Conviction Buy at Goldman Sachs
- $229.06 /
-10.67 (-4.45%) - 01/04/23 DA Davidson
- DA Davidson starts Microsoft at Buy, believes ChatGPT can unseat Google Search
- 01/04/23 DA Davidson
- Microsoft initiated with a Buy at DA Davidson
- 01/04/23 UBS
- Microsoft downgraded to Neutral from Buy at UBS
- 12/22/22 Needham
- Netflix 2023 estimates cut at Needham
- 01/04/23 Wells Fargo
- Wells Fargo downgrades Target to Equal Weight, lowers price target to $142
- 01/04/23 Wells Fargo
- Target downgraded to Equal Weight from Overweight at Wells Fargo
- 12/21/22
- Gordon Haskett downgrades Target on 'meaningfully eroded' traffic
- 12/21/22
- Target downgraded to Hold from Buy at Gordon Haskett
- 01/04/23 Jefferies
- Boston Beer downgraded to Underperform from Hold at Jefferies
- 12/06/22 Deutsche Bank
- Boston Beer downgraded to Sell from Hold at Deutsche Bank
- 11/07/22 Morgan Stanley
- Boston Beer initiated with an Underweight at Morgan Stanley
- 10/24/22 UBS
- Boston Beer price target raised to $412 from $312 at UBS
- 01/04/23 Barclays
- Barclays upgrades Veeva to Overweight as defensive pick
- 01/04/23 Barclays
- Veeva upgraded to Overweight from Equal Weight at Barclays
- 12/06/22 TD Cowen
- Veeva initiated with a Market Perform at Cowen
- 12/05/22 KeyBanc
- Veeva price target lowered to $210 from $220 at KeyBanc
- 01/04/23 BofA
- BioMarin price target raised to $200, added to 'US 1 List' at BofA
- 01/04/23 BofA
- Pfizer downgraded to Neutral at BofA on COVID-19 uncertainty
- 01/04/23 BofA
- Pfizer downgraded to Neutral from Buy at BofA
- 01/03/23 Needham
- Vaxcyte named as Top Pick, added to Conviction list at Needham
- 01/04/23 Wedbush
- Wedbush raises Geron price target to $6 following Phase 3 IMerge study data
- 10/28/22 Wedbush
- Wedbush starts Geron with Outperform, $5 price target
- 10/27/22 Wedbush
- Geron initiated with an Outperform at Wedbush
- 07/28/22 B. Riley
- Geron resumed with a Buy at B. Riley
- $11.08 /
+1.135 (+11.41%) - 01/04/23 Jefferies
- Jefferies upgrades Hayward to Buy after 64% selloff in 2022
- 01/03/23 Jefferies
- Hayward upgraded to Buy from Hold at Jefferies
- 12/12/22 Stifel
- Hayward initiated with a Buy at Stifel
- 10/18/22 BofA
- Hayward downgraded to Underperform at BofA
- 01/04/23 Jefferies
- Vera Therapeutics downgraded to Hold from Buy at Jefferies
- 01/04/23 Wedbush
- Wedbush downgrades Vera Therapeutics to Neutral, lowers price target to $8
- 01/04/23 Wedbush
- Vera Therapeutics downgraded to Neutral from Outperform at Wedbush
- 01/04/23 H.C. Wainwright
- Vera Therapeutics price target lowered to $15 from $36 at H.C. Wainwright
- 12/16/22 Mizuho
- Mobileye price target raised to $40 from $35 at Mizuho
- 12/13/22 JPMorgan
- Mobileye initiated with an Overweight at JPMorgan
- 12/08/22 Baird
- Mobileye price target raised to $39 from $36 at Baird
- 12/05/22 Tigress Financial
- Mobileye initiated with a Buy at Tigress Financial
- 01/04/23 BofA
- ZoomInfo downgraded to Neutral from Buy at BofA
- 12/08/22 Mizuho
- ZoomInfo price target lowered to $45 from $50 at Mizuho
- 12/07/22 Canaccord
- ZoomInfo price target lowered to $43 from $48 at Canaccord
- 11/23/22 RBC Capital
- ZoomInfo price target lowered to $36 from $50 at RBC Capital
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/31/22 Stifel
- Perion Network resumed with a Buy at Stifel
- 01/04/23 Needham
- SGH price target raised to $25 from $23 at Needham
- 01/04/23 Deutsche Bank
- SGH price target lowered to $20 from $24 at Deutsche Bank
- 01/04/23 Barclays
- SGH price target raised to $20 from $15 at Barclays
- 10/25/22 Needham
- SGH price target lowered to $23 from $30 at Needham
- $198.85 /
+9.375 (+4.95%) - 05/18/22 Baird
- UniFirst price target lowered to $195 from $213 at Baird
- 04/01/22 JPMorgan
- UniFirst downgraded to sell on missed earnings pattern at JPMorgan
- 04/01/22 JPMorgan
- UniFirst downgraded to Underweight from Neutral at JPMorgan
- 11/30/22 JonesResearch
- Theratechnologies initiated with a Buy at JonesTrading
- 11/17/22 Cantor Fitzgerald
- Theratechnologies initiated with an Overweight at Cantor Fitzgerald
- 07/15/22 National Bank
- Theratechnologies price target lowered to C$3.25 from C$3.75 at National Bank
- 01/04/23 Barclays
- Deciphera price target raised to $9 from $8 at Barclays
- 01/04/23 Guggenheim
- Deciphera upgraded to Buy from Neutral at Guggenheim
- 01/04/23 Guggenheim
- Deciphera upgraded to Buy from Neutral at Guggenheim
- 09/27/22 Stifel
- Deciphera price target raised to $18 from $11 at Stifel
- 11/01/22
- ZoomInfo raises FY22 EPS view to 83c-84c from 78c-80c
- 11/01/22
- ZoomInfo sees Q4 EPS 21c-22c, consensus 21c
- 11/01/22
- ZoomInfo reports Q3 EPS 24c, consensus 20c
- 11/09/22
- Vera Therapeutics reports Q3 EPS (91c), consensus (72c)
- 08/10/22
- Vera Therapeutics reports Q2 EPS (55c) vs (33c) last year
- 12/01/22
- Veeva raises 2023 non-GAAP EPS view to $4.19 from $4.16, consensus $4.15
- 12/01/22
- Veeva reports Q3 non-GAAP EPS $1.13, consensus $1.07
- 08/31/22
- Veeva sees Q3 EPS $1.07-$1.08, consensus $1.07
- 08/31/22
- Veeva raises 2022 non-GAAP EPS view to $4.17 from $4.16, consensus $4.14
- $198.85 /
+9.375 (+4.95%) - 01/04/23
- UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.21
- 01/04/23
- UniFirst reports Q1 adjusted EPS $2.21, consensus $1.94
- 10/19/22
- UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.72
- 10/19/22
- UniFirst reports Q4 adjusted EPS $1.79, consensus $1.73
- 10/25/22
- Texas Instruments sees Q4 EPS $1.83-$2.11, consensus $2.21
- 10/25/22
- Texas Instruments reports Q3 EPS $2.47, consensus $2.39
- 07/26/22
- Texas Instruments sees Q3 EPS $2.23-$2.51, consensus $2.26
- 07/26/22
- Texas Instruments reports Q2 EPS $2.45, consensus $2.12
- 10/13/22
- TSMC sees Q4 revenue $19.9B-$20.7B, consensus $19.76B
- 10/13/22
- TSMC reports Q3 EPS $1.79, consensus $1.41
- 07/14/22
- TSMC sees Q3 revenue $19.8B-$20.6B, consensus $19.21B
- 07/14/22
- TSMC reports Q2 EPS $1.55, consensus $1.47
- 11/01/22
- Toyota sees FY23 EPS 172.28, revenue Y36T
- 11/01/22
- Toyota reports 1H EPS Y85.42 vs. Y109.28 last year
- 08/04/22
- Toyota sees FY23 EPS Y171.95, revenue Y34.5T
- 08/04/22
- Toyota reports Q1 EPS Y53.54 vs. Y64.23 last year
- 01/04/23
- Theratechnologies sees 2023 revenue $90M-$95M, consensus $95.44M
- 01/04/23
- Theratechnologies sees 2022 revenue $80M, consensus $79.38M
- 10/13/22
- Theratechnologies on track for 2022 revenue guidance $79M-$82M, two est. $81.2M
- 10/13/22
- Theratechnologies reports Q3 revenue $20.8M vs. $17.9M last year
- 11/16/22
- Target on track to deliver total sales of well over $100B this year, says COO
- 11/16/22
- Target reports Q3 adjusted EPS $1.54, consensus $2.13
- 11/15/22
- Notable companies reporting before tomorrow's open
- 01/03/23
- SGH sees Q2 adjusted EPS 60c, plus or minus 15c, consensus 57c
- 01/03/23
- SGH reports Q1 adjusted EPS 79c, consensus 57c
- 10/04/22
- SGH sees Q1 adjusted EPS 60c, plus or minus 15c, consensus 76c
- 10/04/22
- SGH reports Q4 adjusted EPS 80c, consensus 65c
- 10/20/22
- Boston Beer narrows FY22 adj EPS view to $7.00 to $10.00 from $6.00-$11.00
- 10/20/22
- Boston Beer reports Q3 EPS $2.21, consensus $3.07
- 07/21/22
- Boston Beer cuts FY22 adjusted EPS view to $6.00-$11.00 from $11.00-$16.00
- 07/21/22
- Boston Beer reports Q2 EPS $4.31, consensus $4.59
- 11/02/22
- Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42
- 11/02/22
- Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13
- 07/27/22
- Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23
- 11/01/22
- Pfizer raises FY22 adjusted EPS view to $6.40-$6.50 from $6.30-$6.45
- 11/01/22
- Pfizer reports Q3 adjusted EPS $1.78, consensus $1.39
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 11/08/22
- News Corp. reports Q1 adjusted EPS 12c, consensus 15c
- 08/08/22
- News Corp. reports Q4 adjusted EPS 37c, consensus 7c
- 11/16/22
- Nvidia sees Q4 revenue $6B, +/- 2%, consensus $6.09B
- 11/16/22
- Nvidia reports Q3 EPS 58c, consensus 69c
- 11/16/22
- Notable companies reporting after market close
- 08/24/22
- Nvidia down 5% after Q2 report, Q3 guidance
- 12/21/22
- Micron sees Q2 EPS (72c) to (52c), consensus (30c)
- 12/21/22
- Micron reports Q1 EPS (4c), consensus (1c)
- 12/21/22
- Notable companies reporting after market close
- 09/29/22
- Micron sees Q2 revenue range similar to Q1
- $229.06 /
-10.67 (-4.45%) - 10/25/22
- Microsoft sees FX decreasing total revenue growth by 5% in FY23
- 10/25/22
- Microsoft reports Q1 EPS $2.35, consensus $2.30
- 10/25/22
- Notable companies reporting after market close
- 07/26/22
- Microsoft sees FY23 revenue growth in double digits, consensus $225.98B
- 12/01/22
- Marvell sees Q4 adjusted EPS 46c +/- 5c, consensus 62c
- 12/01/22
- Marvell reports Q3 adjusted EPS 57c, consensus 59c
- 12/01/22
- Notable companies reporting after market close
- 08/25/22
- Marvell sees Q3 adjusted EPS 59c +/- 3c, consensus 60c
- $125.17 /
+2.675 (+2.18%) - 10/25/22
- 3M cuts FY22 adjusted EPS view to $10.10-$10.35 from $10.30-$10.80
- 10/25/22
- 3M reports Q3 adjusted EPS $2.69, consensus $2.60
- 10/24/22
- Notable companies reporting before tomorrow's open
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 10/26/22
- Meta Platforms sees Q4 revenue $30B-$32.5B, consensus $32.31B
- 10/26/22
- Meta Platforms reports Q3 EPS $1.64, consensus $1.89
- 10/26/22
- Notable companies reporting after market close
- 11/28/22
- Microchip back Q3 EPS view $1.54-$1.56, consensus $1.58
- 11/03/22
- Microchip sees Q3 EPS $1.54-$1.56, consensus $1.45
- 11/03/22
- Microchip reports Q2 EPS $1.46, consensus $1.44
- 11/03/22
- Notable companies reporting after market close
- 12/07/22
- Mobileye sees Q4 revenue $527M-$545M, consensus $483.72M
- 12/07/22
- Mobileye sees FY22 revenue $1.831B-$1.849B, consensus $1.78B
- 12/07/22
- Mobileye reports Q3 EPS (6c), consensus 12c
JEF Jefferies Financial Group - $38.70 /
+4.485 (+13.11%) - 09/28/22
- Jefferies Financial Group reports Q3 adjusted EPS $1.10, consensus 73c
- 12/05/22
- Intel sees down Q1 sales down 5%-7% as 'right starting point for seasonality'
- 10/27/22
- Intel sees Q4 adjusted EPS 20c, consensus 66c
- 10/27/22
- Intel cuts FY22 adjusted EPS view to $1.95 from $2.30
- 10/27/22
- Intel cuts FY revenue view to $63B-$64B from $65B-$68B
- 11/02/22
- Robinhood reports Q3 EPS (20c), consensus (31c)
- 11/02/22
- Notable companies reporting after market close
- 08/03/22
- Notable companies reporting after market close
- 08/02/22
- Robinhood reports Q2 EPS (34c), consensus (37c)
- $11.08 /
+1.135 (+11.41%) - 07/28/22
- Hayward lowers FY22 revenue growth view to (6%)-(2%) from 9%-12%
- 07/28/22
- Hayward reports Q2 EPS 29c, consensus 35c
- 11/17/22
- General Motors narrows FY22 EBIT-adjusted view to $13.5B-$14.5B from $13B-$15B
- 10/25/22
- General Motors backs FY22 adjusted EPS view $6.50-$7.50, consensus $6.79
- 10/25/22
- General Motors reports Q3 adjusted EPS $2.25, consensus $1.88
- 11/03/22
- Geron reports Q3 EPS (10c), consensus (9c)
- 08/11/22
- Geron reports Q2 EPS (7c), consensus (9c)
- $70.18 /
-14.845 (-17.46%) - 10/25/22
- General Electric sees FY22 adjusted EPS $2.40-$2.80, consensus $2.63
- 10/25/22
- General Electric reports Q3 adjusted EPS 35c, consensus 46c
- 11/01/22
- Fox Corp. reports Q1 adjusted EPS $1.21, consensus $1.14
- 10/31/22
- Notable companies reporting before tomorrow's open
- 08/10/22
- Fox Corp. reports Q4 adjusted EPS 74c, consensus 76c
- 01/03/23
- Deciphera sees FY22 revenue roughly $134M, consensus $132.52M
- 01/03/23
- Deciphera sees Q4 revenue roughly $36M, consensus $34.83M
- 11/03/22
- Deciphera reports Q3 EPS (55c), consensus (58c)
- 08/04/22
- Deciphera reports Q2 EPS (60c), consensus (66c)
- 11/30/22
- Salesforce raises FY23 EPS view to $4.92-$4.94, consensus $4.73
- 11/30/22
- Salesforce sees Q4 EPS $1.35-$1.37, consensus $1.34
- 11/30/22
- Salesforce reports Q3 EPS $1.40, consensus $1.21
- 11/30/22
- Notable companies reporting after market close
- $103.98 /
+12.025 (+13.08%) - 11/17/22
- Alibaba reports Q2 adjusted EPS $1.82, consensus $1.64
- 11/16/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- Alibaba reports Q1 adjusted EPS $1.75, consensus $1.53
- 11/01/22
- AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M
- 11/01/22
- AMD sees Q4 revenue $5.5B +/- $300M, consensus $5.85B
- 11/01/22
- AMD reports Q3 EPS 67c, consensus 68c
- 11/01/22
- Notable companies reporting after market close
- $26.15 /
+3.125 (+13.57%) - 11/02/22
- ACI Worldwide backs FY22 revenue view $1.4B-$1.42B, consensus $1.46B
- 11/02/22
- ACI Worldwide reports Q3 adjusted EPS 11c, consensus 20c
- 09/01/22
- ACI Worldwide lowers FY22 revenue view to $1.4B-$1.42B from $1.415B-$1.435B
- 09/01/22
- ACI Worldwide lowers Q3 revenue view to $306M-$321M from $310M-$325M
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 11/16/22
- ZoomInfo sees 4% sequential growth in Q4, possible 4%-5% per quarter in 2023
- 11/16/22
- ZoomInfo Technologies trading resumes
- 11/16/22
- ZoomInfo Technologies trading halted, volatility trading pause
- 11/16/22
- ZoomInfo down 15% following conference presentation
- 01/03/23
- Vera Therapeutics shares fall 67% despite ORIGIN trial meeting primary endpoint
- 01/03/23
- Vera Therapeutics announces ORIGIN clinical trial met primary endpoint
- 11/17/22
- Vera Therapeutics to host KOL webinar on targeting the source of IgAN
- 11/09/22
- Vera Therapeutics expects cash to fund oeprations into 2Q24
- 12/08/22
- Veeva director sells $1.64M in common stock
- 12/02/22
- Veeva falls -7.3%
- 11/01/22
- Veeva, Merck establish ten-year strategic partnership agreement
- 10/04/22
- Veeva announces over 350 companies using Veeva Vault RIM Suite applications
- 10/25/22
- UniFirst increases quarterly common stock dividend to 31c per share
- 12/11/22
- Fly Intel: Top five weekend stock stories
- 11/28/22
- Texas Instruments announces expansion of its portfolio
- 10/25/22
- Texas Instruments falls 5% to $154.39 after Q4 guidance misses estimates
- 10/25/22
- Texas Instruments: Experienced expected weakness in personal electronics in Q3
- 12/06/22
- TSMC to triple U.S. chip investment to $40B
- 11/14/22
- TSMC jumps 7% to $77.91 after Berkshire Hathaway disclosed added stake
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 10/26/22
- Synopsys, TSMC partner over multi-die design solutions
- 01/04/23
- Theratechnologies focused on achieving positive EBITDA in the near-term
- 01/04/23
- Theratechnologies forms committee for Protocol Amendment for TH1902 trial
- 01/04/23
- Theratechnologies CEO says positioned 'product portfolio for commercial success'
- 12/01/22
- Theratechnologies trading resumes
- 12/22/22
- Target recalls roughly 204,000 children's weighted blankets after two deaths
- 11/25/22
- Target announces Cyber Monday sales event from Nov. 27-28
- 11/17/22
- Target announces largest Black Friday week sale ever from Nov. 20-26
- 11/16/22
- Target falls -15.8%
- 01/03/23
- SGH spikes almost 9% after reporting Q1 results that beat expectations
- 11/16/22
- SGH's Penguing Computing to acquire software assets from Colorado Code Craft
- 09/14/22
- Cree LED, Tomar Electronics enter settlement, limited license agreement
- 07/28/22
- SGH CEO buys $181K in common stock stock
- 12/12/22
- Boston Beer's TeaPot launches merchandise collaboration with Peace Collective
- 07/21/22
- Boston Beer drops 10% to $303.40 after lowering FY22 EPS guidance
- 01/04/23
- Visteon, Qualcomm collaborate on development of digital cockpit
- 11/02/22
- Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates
- 11/02/22
- Qualcomm sees low-double digits handset volume declines for 2022
- 10/25/22
- Cognizant expands collaboration with Qualcomm
- 12/29/22
- Pfizer discloses 5.38M share stake in Oric Pharmaceuticals
- 12/29/22
- Pfizer announces topline results from Phase 3 study of fidanacogene elaparvovec
- 12/28/22
- Pfizer announces FDA acceptance of BLA for MenABCWY in adolescents
- 12/26/22
- Fly Intel: Top five weekend stock stories
- 01/03/23
- Foxconn, Nvidia partner to build automated electric vehicles
- 12/14/22
- IonQ hires Rima Alameddine as Chief Revenue Officer
- 12/07/22
- KULR Technology expands KULR VIBE offering with AI server platform
- 01/02/23
- Fly Intel: Top five weekend stock stories
- 12/30/22
- Micron slides 2% to $49.60 in pre-market after Argus downgrade to Hold
- 12/21/22
- Micron suspends share buybacks
- 12/21/22
- Micron slips about 1% to $50.70 after Q1 earnings miss and guidance
- $229.18 /
-10.55 (-4.40%) - 12/28/22
- Third Activision Blizzard video game unit seeks union
- 12/18/22
- Fly Intel: Top five weekend stock stories
- 12/16/22
- ReNew Energy Global signs 150 MW agreement with Microsoft
- 12/15/22
- Microsoft names Melanie Nakagawa as new Chief Sustainability Officer
- 12/01/22
- Marvell falls 7% to $42.29 after Q3 results, Q4 guidance miss estimates
- 12/01/22
- Marvell reports Q3 adjusted gross margin 64%
- 11/30/22
- Marvell extends collaboration with Nokia
- 10/03/22
- Marvell CEO Carl Hull to switch roles, William Martin to succeed
- 01/04/23
- Immutep achieves 50% enrollment milestone in Phase IIB TACTI-003 trial
- 12/30/22
- FDA determines Evaxion Biotech can proceed with Phase 2B trial of EVX-01
- 12/22/22
- Merck and Kelun Biotech sign license and collaboration agreement in cancer
- 12/21/22
- AstraZeneca's Lynparza approved in E.U. as first line treatment in mCRPC
- 12/20/22
- 3M to exit PMAS manufacturing by 2025
- 11/21/22
- 3M announces reseller agreement with Rad AI
- 11/10/22
- California AG sues DuPont, 3M over 'toxic forever chemicals'
- 10/13/22
- 3M V.A.C. Therapy NPWT achieves medical evidence milestone
- 01/04/23
- Irish Data Protection Commission reports conclusion of inquiries into Meta
- 01/04/23
- Meta to appeal both 'substance' of Irish DPC rulings and fines
- 12/23/22
- Meta to settle Cambridge Analytica scandal case for $725M
- 12/19/22
- EU sends Statement of Objections to Meta over 'abusive practices' in Marketplace
- 11/10/22
- Microchip announces LAN8840, LAN8841 Gigabit Ethernet transceiver devices
- 10/26/22
- Microchip announces PIC32CXMT family of 32-bit microprocessors
- 10/19/22
- Microchip intoduces Arm Cortex - M4F-based PIC MCU family
- 09/19/22
- Microchip announces META-DX2 Ethernet PHY portfolio
- 01/04/23
- Mobileye in pact with Wistron NeWeb for software-defined imaging radars
- 10/31/22
- Mobileye CEO buys $10M in common stock
- 10/27/22
- Intel reports Q3 Mobileye revenue $450M
- 12/30/22
- Southwest says schedule normal today, sees 'minimal disruptions'
- 12/29/22
- Southwest sees returning to normal on Friday, sets up reimbursement page
- 12/27/22
- Southwest sees flying roughly one third of schedule for 'next several days'
- 01/03/23
- Intel announces 13th Gen Core mobile processors plus N-series at CES
- 12/29/22
- Check Point expands collaboration with Intel for anti-ransomware capabilities
- 11/29/22
- Synopsys appoints Shelagh Glaser as CFO
- 01/04/23
- Hayward rises 9.6%
- 11/01/22
- Hayward rises 13.2%
- 01/03/23
- Federal regulators issue joint statement on crypto-asset risks to banks
- 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 11/29/22
- Stack Capital invests $8M in Locus Robotics
- 11/22/22
- Goldman Sachs Asset Management to pay $4M penalty to settle SEC charges
- 01/04/23
- Geron up 48% in pre-market at $3.54 after Phase 3 trial data for imetelstat
- 01/04/23
- Geron reports 'positive' results from IMerge Phase 3 trial of imetelstat
- 08/22/22
- Geron doses first patient in IMproveMF phase 1 study
- 01/04/23
- GE HealthCare completes spin-off from GE, starts trading on Nasdaq
- 12/28/22
- GE HealthCare to replace Vornado Realty Trust in the S&P500 at open on January 4
- 11/30/22
- General Electric board approves separation of GE HealthCare
- $68.70 /
-16.33 (-19.21%) - 01/04/23
- General Electric falls -19.3%
- 01/04/23
- General Electric falls -21.0%
- 01/04/23
- General Electric falls -20.0%
- $18.82 /
+2.875 (+18.04%) - 01/03/23
- Deciphera announces results from ctDNA analysis from Intrigue Phase 3 trial
- 09/11/22
- Deciphera presents updated Phase 1/2 Data for vimseltinib in TGCT
- 09/10/22
- Deciphera presnts initial Phase 1 single agent dose escalation data for DCC-3116
- 08/10/22
- Deciphera announces publication of INTRIGUE study results in journal
- 01/04/23
- Salesforce up 4% to $139.85 after announcing restructuring
- 01/04/23
- Salesforce announces restructuring, 10% workforce reduction
- 12/08/22
- Salesforce CEO: Planning for CRM to be second largest software company
- 12/06/22
- Sprout, Salesforce deepen partnership with addition of Tableau
COLL Collegium Pharmaceutical - 01/04/23
- Collegium Pharmaceutical board authorizes $100M share repurchase program
- 12/22/22
- Collegium Pharmaceutical says appeals court affirms validity of Belbuca patents
- $101.65 /
+9.695 (+10.54%) - 12/29/22
- Alibaba names new CTO as CEO steps in interim cloud head
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 12/23/22
- PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline
- 11/17/22
- Tims China announces partnership with Alibaba's Freshippo
AUPH Aurinia Pharmaceuticals - 01/03/23
- Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical
- 11/30/22
- Aurinia announces U.K. marketing authorization of Lupkynis
- 09/19/22
- Aurinia announces European Commission approval of LUPKYNIS
- 07/26/22
- Aurinia says USPTO to institute trial on Inter Partes review of Lupkynis patent
- 12/20/22
- EU opens antitrust probe into Broadcom's proposed $61B VMware bid
- 12/01/22
- AMD, Viettel collaborate on 5G mobile network expansion
- 11/23/22
- Third quarter CPU shipments down 18.6% compared to Q321, JPR says
- 11/17/22
- AMD, Analog Devices resolve all ongoing patent litigations
- 12/08/22 Baird
- Baird downgrades Salesforce on macro, executive turnover concerns
- 12/08/22 Baird
- Salesforce downgraded to Neutral from Outperform at Baird
- 12/05/22 KeyBanc
- Veeva price target lowered to $210 from $220 at KeyBanc
- 12/05/22 Credit Suisse
- Salesforce price target lowered to $225 from $250 at Credit Suisse
- 01/02/23 Rosenblatt
- Rosenblatt reveals 15 best stock ideas for 2023
- 12/30/22 Argus
- Argus cuts Micron to Hold, sees potential operating losses over coming quarters
- 12/30/22 Oppenheimer
- Oppenheimer remain buyers of Enovix after CEO announcement
- 12/30/22 Argus
- Micron downgraded to Hold from Buy at Argus
- $101.65 /
+9.695 (+10.54%) - 11/18/22 Benchmark
- Alibaba price target lowered to $180 from $206 at Benchmark
- 11/18/22 UBS
- Alibaba price target lowered to $135 from $140 at UBS
- 11/18/22 Truist
- Alibaba price target lowered to $120 from $125 at Truist
- 11/18/22 Baird
- Alibaba price target lowered to $120 from $140 at Baird
- 12/15/22 Morgan Stanley
- AMD named 'Top Pick' in Semiconductors at Morgan Stanley
- 11/15/22 Credit Suisse
- Intel assumed with a Neutral at Credit Suisse
- 11/15/22 Credit Suisse
- AMD assumed with an Outperform at Credit Suisse
- 12/13/22 Northland
- Northland starts FormFactor at Outperform with $33 price target
- 12/01/22 New Street
- Mobileye initiated with a Buy at New Street
- 11/22/22 Mizuho
- Intel resumed with a Neutral at Mizuho
- 11/21/22 Morgan Stanley
- Mobileye initiated with an Equal Weight at Morgan Stanley
- 12/02/22 Craig-Hallum
- Marvell price target lowered to $63 from $90 at Craig-Hallum
- 12/02/22 BMO Capital
- Marvell price target lowered to $65 from $75 at BMO Capital
- 12/02/22 Jefferies
- Jefferies would 'buy the confession' after Marvell guidance miss
- 11/29/22 Stifel
- Microchip price target raised to $80 from $77 at Stifel
- 11/15/22 Credit Suisse
- Microchip initiated with a Neutral at Credit Suisse
- 11/04/22 UBS
- Microchip price target lowered to $90 from $100 at UBS
- 11/03/22 Piper Sandler
- Microchip price target lowered to $80 from $100 at Piper Sandler
- 12/19/22 Needham
- Nvidia price target raised to $230 from $200 at Needham
- 12/15/22 HSBC
- Nvidia initiated with a Reduce at HSBC
- 12/14/22 Deutsche Bank
- Nvidia price target raised to $170 from $150 at Deutsche Bank
- 12/20/22 JPMorgan
- Qualcomm price target lowered to $160 from $185 at JPMorgan
- 12/12/22 Wells Fargo
- Wells Fargo downgrades Qualcomm to Underweight with $105 price target
- 12/12/22 Wells Fargo
- Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo
- 11/15/22 Credit Suisse
- Qualcomm initiated with an Outperform at Credit Suisse
- 12/14/22 Deutsche Bank
- Texas Instruments price target raised to $158 from $155 at Deutsche Bank
- 11/15/22 Credit Suisse
- Texas Instruments assumed with Neutral from Outperform at Credit Suisse
- 11/01/22 Craig-Hallum
- Lattice Semiconductor price target lowered to $50 from $58 at Craig-Hallum
- 10/26/22 Susquehanna
- Texas Instruments price target lowered to $195 from $215 at Susquehanna
- 11/18/22 Erste Group
- TSMC upgraded to Buy from Hold at Erste Group
- 10/17/22 Northland
- Teradyne price target lowered to $74 from $85 at Northland
- 10/13/22 Goldman Sachs
- TSMC downgraded to Buy from Conviction Buy at Goldman Sachs
- 12/06/22 Oppenheimer
- General Electric upgraded to Outperform from Perform at Oppenheimer
- $68.70 /
-16.33 (-19.21%) - 12/16/22 Barclays
- General Electric price target raised to $96 from $92 at Barclays
- 12/09/22 RBC Capital
- General Electric price target raised to $98 from $93 at RBC Capital
- 12/09/22 Citi
- General Electric price target raised to $100 from $87 at Citi
- 12/08/22 Oppenheimer
- Oppenheimer backs Outperform on GE amid weakness
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/31/22 Stifel
- Perion Network resumed with a Buy at Stifel
- 01/04/23 New Street
- New Street starts Meta Platforms with a Buy, thinks ad revenue can outperform
- 01/03/23 New Street
- Meta Platforms initiated with a Buy at New Street
- 12/16/22 JPMorgan
- Meta Platforms upgraded to Overweight from Neutral at JPMorgan
- 11/15/22 Morgan Stanley
- Meta Platforms price target lowered to $100 from $105 at Morgan Stanley
AUPH Aurinia Pharmaceuticals - 01/03/23 RBC Capital
- Aurinia price target raised to $11 from $10 at RBC Capital
- 11/07/22 H.C. Wainwright
- Aurinia Pharmaceuticals price target lowered to $14 from $26 at H.C. Wainwright
- 11/04/22 Oppenheimer
- Oppenheimer downgrades Aurinia on commercial challenges
- 11/04/22 Oppenheimer
- Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- 12/09/22 Citi
- 3M price target raised to $126 from $117 at Citi
- 11/16/22
- 3M followers suggest 'company might be ripe for activist,' says Gordon Haskett
- 10/26/22 Deutsche Bank
- 3M price target raised to $127 from $126 at Deutsche Bank
- 10/26/22 Mizuho
- 3M price target lowered to $130 from $140 at Mizuho
- $229.18 /
-10.55 (-4.40%) - 01/04/23 UBS
- Microsoft downgraded to Neutral from Buy at UBS
- 12/22/22 Needham
- Netflix 2023 estimates cut at Needham
- 12/20/22 Oppenheimer
- Oppenheimer reiterates bullish stance on Netflix's ad tier driving sub growth
- 12/15/22 Wedbush
- Wedbush initiates Zoom Video with a Neutral and $80 price target
- 12/16/22 Goldman Sachs
- Southwest resumed with a Neutral at Goldman Sachs
- 12/15/22 TD Cowen
- Copa Holdings upgraded to Outperform at Cowen amid airlines rating shake-up
- 12/08/22 Susquehanna
- Southwest guidance suggests risk around order book, says Susquehanna
- 12/08/22 Deutsche Bank
- Southwest price target raised to $62 from $60 at Deutsche Bank
- 01/04/23 Wolfe Research
- Goldman Sachs downgraded to Peer Perform from Outperform at Wolfe Research
- 01/03/23 Barclays
- Goldman Sachs price target raised to $495 from $410 at Barclays
- 12/28/22 Oppenheimer
- Goldman Sachs price target lowered to $492 from $512 at Oppenheimer
- 12/14/22 Wells Fargo
- Goldman Sachs price target raised to $400 from $380 at Wells Fargo
- 01/04/23 Needham
- SGH price target raised to $25 from $23 at Needham
- 01/04/23 Deutsche Bank
- SGH price target lowered to $20 from $24 at Deutsche Bank
- 01/04/23 Barclays
- SGH price target raised to $20 from $15 at Barclays
- 10/25/22 Needham
- SGH price target lowered to $23 from $30 at Needham
- 05/18/22 Baird
- UniFirst price target lowered to $195 from $213 at Baird
- 04/01/22 JPMorgan
- UniFirst downgraded to sell on missed earnings pattern at JPMorgan
- 04/01/22 JPMorgan
- UniFirst downgraded to Underweight from Neutral at JPMorgan
- 03/31/22 Baird
- UniFirst weakness a buying opportunity, says Baird
- 11/30/22 JonesResearch
- Theratechnologies initiated with a Buy at JonesTrading
- 11/17/22 Cantor Fitzgerald
- Theratechnologies initiated with an Overweight at Cantor Fitzgerald
- 07/15/22 National Bank
- Theratechnologies price target lowered to C$3.25 from C$3.75 at National Bank
- $18.82 /
+2.875 (+18.04%) - 01/04/23 Barclays
- Deciphera price target raised to $9 from $8 at Barclays
- 01/04/23 Guggenheim
- Deciphera upgraded to Buy from Neutral at Guggenheim
- 01/04/23 Guggenheim
- Deciphera upgraded to Buy from Neutral at Guggenheim
- 09/27/22 Stifel
- Deciphera price target raised to $18 from $11 at Stifel
COLL Collegium Pharmaceutical - 08/08/22 H.C. Wainwright
- Collegium Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
- 02/22/22 Piper Sandler
- Collegium Pharmaceutical price target raised to $42 from $36 at Piper Sandler
- 02/15/22 Piper Sandler
- BioDelivery Sciences downgraded to Neutral from Overweight at Piper Sandler
- 02/15/22 Needham
- Collegium Pharmaceutical price target raised to $34 from $28 at Needham
- 01/04/23 Wells Fargo
- Wells Fargo downgrades Target to Equal Weight, lowers price target to $142
- 01/04/23 Wells Fargo
- Target downgraded to Equal Weight from Overweight at Wells Fargo
- 12/21/22
- Gordon Haskett downgrades Target on 'meaningfully eroded' traffic
- 12/21/22
- Target downgraded to Hold from Buy at Gordon Haskett
- 01/04/23 Jefferies
- Boston Beer downgraded to Underperform from Hold at Jefferies
- 12/06/22 Deutsche Bank
- Boston Beer downgraded to Sell from Hold at Deutsche Bank
- 11/07/22 Morgan Stanley
- Boston Beer initiated with an Underweight at Morgan Stanley
- 10/24/22 UBS
- Boston Beer price target raised to $412 from $312 at UBS
- 01/04/23 Barclays
- Barclays upgrades Veeva to Overweight as defensive pick
- 01/04/23 Barclays
- Veeva upgraded to Overweight from Equal Weight at Barclays
- 12/06/22 TD Cowen
- Veeva initiated with a Market Perform at Cowen
- 01/04/23 BofA
- BioMarin price target raised to $200, added to 'US 1 List' at BofA
- 01/04/23 BofA
- Pfizer downgraded to Neutral at BofA on COVID-19 uncertainty
- 01/04/23 BofA
- Pfizer downgraded to Neutral from Buy at BofA
- 01/03/23 Needham
- Vaxcyte named as Top Pick, added to Conviction list at Needham
- 01/04/23 BofA
- Merck upgraded to Buy at BofA on consistent revenue upside
- 01/04/23 BofA
- Merck upgraded to Buy from Neutral at BofA
- 01/03/23 Wells Fargo
- Merck price target raised to $125 from $110 at Wells Fargo
- 01/03/23 TD Cowen
- Merck price target raised to $120 from $108 at Cowen
- 01/04/23 Wedbush
- Wedbush raises Geron price target to $6 following Phase 3 IMerge study data
- 10/28/22 Wedbush
- Wedbush starts Geron with Outperform, $5 price target
- 10/27/22 Wedbush
- Geron initiated with an Outperform at Wedbush
- 07/28/22 B. Riley
- Geron resumed with a Buy at B. Riley
- 01/04/23 Jefferies
- Jefferies upgrades Hayward to Buy after 64% selloff in 2022
- 01/03/23 Jefferies
- Hayward upgraded to Buy from Hold at Jefferies
- 12/12/22 Stifel
- Hayward initiated with a Buy at Stifel
- 10/18/22 BofA
- Hayward downgraded to Underperform at BofA
- 01/04/23 Jefferies
- Vera Therapeutics downgraded to Hold from Buy at Jefferies
- 01/04/23 Wedbush
- Wedbush downgrades Vera Therapeutics to Neutral, lowers price target to $8
- 01/04/23 Wedbush
- Vera Therapeutics downgraded to Neutral from Outperform at Wedbush
- 01/04/23 H.C. Wainwright
- Vera Therapeutics price target lowered to $15 from $36 at H.C. Wainwright
- 12/16/22 Mizuho
- Mobileye price target raised to $40 from $35 at Mizuho
- 12/13/22 JPMorgan
- Mobileye initiated with an Overweight at JPMorgan
- 12/08/22 Baird
- Mobileye price target raised to $39 from $36 at Baird
- 12/05/22 Tigress Financial
- Mobileye initiated with a Buy at Tigress Financial
- 01/04/23 BofA
- ZoomInfo downgraded to Neutral from Buy at BofA
- 12/08/22 Mizuho
- ZoomInfo price target lowered to $45 from $50 at Mizuho
- 12/07/22 Canaccord
- ZoomInfo price target lowered to $43 from $48 at Canaccord
- 11/23/22 RBC Capital
- ZoomInfo price target lowered to $36 from $50 at RBC Capital
- 11/01/22
- ZoomInfo raises FY22 EPS view to 83c-84c from 78c-80c
- 11/01/22
- ZoomInfo sees Q4 EPS 21c-22c, consensus 21c
- 11/01/22
- ZoomInfo reports Q3 EPS 24c, consensus 20c
- 11/09/22
- Vera Therapeutics reports Q3 EPS (91c), consensus (72c)
- 08/10/22
- Vera Therapeutics reports Q2 EPS (55c) vs (33c) last year
- 12/01/22
- Veeva raises 2023 non-GAAP EPS view to $4.19 from $4.16, consensus $4.15
- 12/01/22
- Veeva reports Q3 non-GAAP EPS $1.13, consensus $1.07
- 08/31/22
- Veeva sees Q3 EPS $1.07-$1.08, consensus $1.07
- 08/31/22
- Veeva raises 2022 non-GAAP EPS view to $4.17 from $4.16, consensus $4.14
- 01/04/23
- UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.21
- 01/04/23
- UniFirst reports Q1 adjusted EPS $2.21, consensus $1.94
- 10/19/22
- UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.72
- 10/19/22
- UniFirst reports Q4 adjusted EPS $1.79, consensus $1.73
- 10/25/22
- Texas Instruments sees Q4 EPS $1.83-$2.11, consensus $2.21
- 10/25/22
- Texas Instruments reports Q3 EPS $2.47, consensus $2.39
- 07/26/22
- Texas Instruments sees Q3 EPS $2.23-$2.51, consensus $2.26
- 07/26/22
- Texas Instruments reports Q2 EPS $2.45, consensus $2.12
- 10/13/22
- TSMC sees Q4 revenue $19.9B-$20.7B, consensus $19.76B
- 10/13/22
- TSMC reports Q3 EPS $1.79, consensus $1.41
- 07/14/22
- TSMC sees Q3 revenue $19.8B-$20.6B, consensus $19.21B
- 07/14/22
- TSMC reports Q2 EPS $1.55, consensus $1.47
- 01/04/23
- Theratechnologies sees 2023 revenue $90M-$95M, consensus $95.44M
- 01/04/23
- Theratechnologies sees 2022 revenue $80M, consensus $79.38M
- 10/13/22
- Theratechnologies on track for 2022 revenue guidance $79M-$82M, two est. $81.2M
- 10/13/22
- Theratechnologies reports Q3 revenue $20.8M vs. $17.9M last year
- 11/16/22
- Target on track to deliver total sales of well over $100B this year, says COO
- 11/16/22
- Target reports Q3 adjusted EPS $1.54, consensus $2.13
- 11/15/22
- Notable companies reporting before tomorrow's open
- 01/03/23
- SGH sees Q2 adjusted EPS 60c, plus or minus 15c, consensus 57c
- 01/03/23
- SGH reports Q1 adjusted EPS 79c, consensus 57c
- 10/04/22
- SGH sees Q1 adjusted EPS 60c, plus or minus 15c, consensus 76c
- 10/04/22
- SGH reports Q4 adjusted EPS 80c, consensus 65c
- 10/20/22
- Boston Beer narrows FY22 adj EPS view to $7.00 to $10.00 from $6.00-$11.00
- 10/20/22
- Boston Beer reports Q3 EPS $2.21, consensus $3.07
- 07/21/22
- Boston Beer cuts FY22 adjusted EPS view to $6.00-$11.00 from $11.00-$16.00
- 07/21/22
- Boston Beer reports Q2 EPS $4.31, consensus $4.59
- 11/02/22
- Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42
- 11/02/22
- Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13
- 11/02/22
- Notable companies reporting after market close
- 07/27/22
- Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23
- 11/01/22
- Pfizer raises FY22 adjusted EPS view to $6.40-$6.50 from $6.30-$6.45
- 11/01/22
- Pfizer reports Q3 adjusted EPS $1.78, consensus $1.39
- 10/31/22
- Notable companies reporting before tomorrow's open
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 11/16/22
- Nvidia sees Q4 revenue $6B, +/- 2%, consensus $6.09B
- 11/16/22
- Nvidia reports Q3 EPS 58c, consensus 69c
- 11/16/22
- Notable companies reporting after market close
- 08/24/22
- Nvidia down 5% after Q2 report, Q3 guidance
- 12/21/22
- Micron sees Q2 EPS (72c) to (52c), consensus (30c)
- 12/21/22
- Micron reports Q1 EPS (4c), consensus (1c)
- 12/21/22
- Notable companies reporting after market close
- 09/29/22
- Micron sees Q2 revenue range similar to Q1
- $229.18 /
-10.55 (-4.40%) - 10/25/22
- Microsoft sees FX decreasing total revenue growth by 5% in FY23
- 10/25/22
- Microsoft reports Q1 EPS $2.35, consensus $2.30
- 10/25/22
- Notable companies reporting after market close
- 07/26/22
- Microsoft sees FY23 revenue growth in double digits, consensus $225.98B
- 12/01/22
- Marvell sees Q4 adjusted EPS 46c +/- 5c, consensus 62c
- 12/01/22
- Marvell reports Q3 adjusted EPS 57c, consensus 59c
- 12/01/22
- Notable companies reporting after market close
- 08/25/22
- Marvell sees Q3 adjusted EPS 59c +/- 3c, consensus 60c
- 10/27/22
- Merck raises FY22 adjusted EPS view to $7.32-$7.37 from $7.25-$7.35
- 10/27/22
- Merck reports Q3 adjusted EPS $1.85, consensus $1.71
- 10/25/22
- 3M cuts FY22 adjusted EPS view to $10.10-$10.35 from $10.30-$10.80
- 10/25/22
- 3M reports Q3 adjusted EPS $2.69, consensus $2.60
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 10/26/22
- Meta Platforms sees Q4 revenue $30B-$32.5B, consensus $32.31B
- 10/26/22
- Meta Platforms reports Q3 EPS $1.64, consensus $1.89
- 10/26/22
- Notable companies reporting after market close
- 11/28/22
- Microchip back Q3 EPS view $1.54-$1.56, consensus $1.58
- 11/03/22
- Microchip sees Q3 EPS $1.54-$1.56, consensus $1.45
- 11/03/22
- Microchip reports Q2 EPS $1.46, consensus $1.44
- 11/03/22
- Notable companies reporting after market close
- 12/07/22
- Mobileye sees Q4 revenue $527M-$545M, consensus $483.72M
- 12/07/22
- Mobileye sees FY22 revenue $1.831B-$1.849B, consensus $1.78B
- 12/07/22
- Mobileye reports Q3 EPS (6c), consensus 12c
- 10/27/22
- Southwest sees FY22 ASMs down 4.5%
- 10/27/22
- Southwest sees Q4 revenue up 13%-17%, consensus $6.23B
- 10/27/22
- Southwest reports Q3 adjusted EPS 50c, consensus 42c
- 10/26/22
- Notable companies reporting before tomorrow's open
- 12/05/22
- Intel sees down Q1 sales down 5%-7% as 'right starting point for seasonality'
- 10/27/22
- Intel sees Q4 adjusted EPS 20c, consensus 66c
- 10/27/22
- Intel cuts FY22 adjusted EPS view to $1.95 from $2.30
- 10/27/22
- Intel cuts FY revenue view to $63B-$64B from $65B-$68B
- 07/28/22
- Hayward lowers FY22 revenue growth view to (6%)-(2%) from 9%-12%
- 07/28/22
- Hayward reports Q2 EPS 29c, consensus 35c
- 10/18/22
- Goldman Sachs reports Q3 EPS $8.25, consensus $7.69
- 10/17/22
- Notable companies reporting before tomorrow's open
- 07/18/22
- Goldman Sachs reports Q2 EPS $7.73, consensus $7.25
- 11/03/22
- Geron reports Q3 EPS (10c), consensus (9c)
- 08/11/22
- Geron reports Q2 EPS (7c), consensus (9c)
- $68.70 /
-16.33 (-19.21%) - 10/25/22
- General Electric sees FY22 adjusted EPS $2.40-$2.80, consensus $2.63
- 10/25/22
- General Electric reports Q3 adjusted EPS 35c, consensus 46c
- 10/24/22
- Notable companies reporting before tomorrow's open
- $18.82 /
+2.875 (+18.04%) - 01/03/23
- Deciphera sees FY22 revenue roughly $134M, consensus $132.52M
- 01/03/23
- Deciphera sees Q4 revenue roughly $36M, consensus $34.83M
- 11/03/22
- Deciphera reports Q3 EPS (55c), consensus (58c)
- 08/04/22
- Deciphera reports Q2 EPS (60c), consensus (66c)
- 11/30/22
- Salesforce raises FY23 EPS view to $4.92-$4.94, consensus $4.73
- 11/30/22
- Salesforce sees Q4 EPS $1.35-$1.37, consensus $1.34
- 11/30/22
- Salesforce reports Q3 EPS $1.40, consensus $1.21
- 11/30/22
- Notable companies reporting after market close
COLL Collegium Pharmaceutical - 01/04/23
- Collegium Pharmaceutical sees 2023 product revenue $565M-$580M
- 11/03/22
- Collegium Pharmaceutical reports Q3 EPS 1c, consensus (13c)
- 08/04/22
- Collegium Pharmaceutical reports Q2 EPS (15c), consensus $1.42
- $101.65 /
+9.695 (+10.54%) - 11/17/22
- Alibaba reports Q2 adjusted EPS $1.82, consensus $1.64
- 11/16/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- Alibaba reports Q1 adjusted EPS $1.75, consensus $1.53
AUPH Aurinia Pharmaceuticals - 11/03/22
- Aurinia Pharmaceuticals lowers FY22 revenue view to $100M-105M from $115M-$135M
- 11/03/22
- Aurinia Pharmaceuticals reports Q3 EPS (6c), consensus (17c)
- 08/04/22
- Aurinia Pharmaceuticals reports Q2 EPS (25c), consensus (22c)
- 11/01/22
- AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M
- 11/01/22
- AMD sees Q4 revenue $5.5B +/- $300M, consensus $5.85B
- 11/01/22
- AMD reports Q3 EPS 67c, consensus 68c
- 11/01/22
- Notable companies reporting after market close
|